Klaus Schomäcker

Prof. Dr. Klaus Schomäcker

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2000 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
KSKlaus Schomäcker
Klaus Schomäcker
HSHarald Schicha
Harald Schicha

9 August 2021 in Molecular Imaging and Biology
Verified
Journal Article
Open access
PDF file
SVSergio Muñoz Vázquez
Sergio Muñoz Vázquez
HEHeike Endepols
Heike Endepols
TFThomas Fischer
Thomas Fischer
STSamir-Ghali Tawadros
Samir-Ghali Tawadros
MHMelanie Hohberg
Melanie Hohberg
KSKlaus Schomäcker
Klaus Schomäcker
Purpose: We present here a Zr-89-labeled inhibitor of prostate-specific membrane antigen (PSMA) as a complement to the already established F-18- or Ga-68-ligands.Procedures: The precursor PSMA-DFO (ABX) was used for Zr-89-labeling. This is not an antibody, but a peptide analogue of the precursor for the production of [177Lu]Lu-PSMA-617. The ligand [89Zr]Zr-PSMA-DFO was compared with [68Ga]Ga-PSMA-11 and [18F]F-JK-PSMA-7in vitroby determination of theKdvalue, cellular uptake, internalization in LNCaP cells, biodistribution studies with LNCaP prostate tumor xenografts in mice, andin vivoby small-animal PET imaging in LNCaP tumor mouse models. A first-in-human PET was performed with [89Zr]Zr-PSMA-DFO on a patient presenting with a biochemical recurrence after brachytherapy and an ambiguous intraprostatic finding with [18F]F-JK-PSMA-7 but histologically benign cells in a prostate biopsy 7 months previously.Results: [89Zr]Zr-PSMA-DFO was prepared with a radiochemical purity ≥ 99.9% and a very highin vitrostability for up to 7 days at 37 °C. All radiotracers showed similar specific cellular binding and internalization,in vitroand comparable tumor uptake in biodistribution experiments during the first 5 h. The [89Zr]Zr-PSMA-DFO achieved significantly higher tumor/background ratios in LNCaP tumor xenografts (tumor/blood: 309 ± 89, tumor/muscle: 450 ± 38) after 24 h than [68Ga]Ga-PSMA-11 (tumor/blood: 112 ± 57, tumor/muscle: 58 ± 36) or [18F]F-JK-PSMA-7 (tumor/blood: 175 ± 30, tumor/muscle: 114 ± 14) after 4 h (p < 0.01). Small-animal PET imaging demonstratedin vivothat tumor visualization with [89Zr]Zr-PSMA-DFO is comparable to [68Ga]Ga-PSMA-11 or [18F]F-JK-PSMA-7 at early time points (1 h p.i.) and that PET scans up to 48 h p.i. clearly visualized the tumor at late time points. A late [89Zr]Zr-PSMA-DFO PET scan on a patient with biochemical recurrence (BCR) had demonstrated intensive tracer accumulation in the right (SUVmax13.25, 48 h p.i.) and in the left prostate lobe (SUV max 9.47), a repeat biopsy revealed cancer cells on both sides.Conclusion: [89Zr]Zr-PSMA-DFO is a promising PSMA PET tracer for detection of tumor areas with lower PSMA expression and thus warrants further clinical evaluation.

17 August 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
KSKlaus Schomäcker
Klaus Schomäcker
FSFerdinand Sudbrock
Ferdinand Sudbrock
TFThomas Fischer
Thomas Fischer
MDMarkus Dietlein
Markus Dietlein
CKCarsten Kobe
Carsten Kobe
HSHarald Schicha
Harald Schicha

28 December 2023 in Molecules
Verified
Journal Article
Open access
PDF file
KSKlaus Schomäcker
Klaus Schomäcker
FDFelix Dietlein
Felix Dietlein
SVSergio Muñoz Vázquez
Sergio Muñoz Vázquez
FBFeodor Braun
Feodor Braun
TFThomas Fischer
Thomas Fischer
MDMarkus Dietlein
Markus Dietlein
The interdisciplinary possibilities inherent in nuclear medicine offer an opportunity for the patient-centered development of radioactive pharmaceuticals based on specific research questions. This approach provides radiopharmaceutical manufacturers with a robust scientific foundation on which to navigate the regulatory requirements for drug approval laid down by the law. A vivid illustration of this interdisciplinary cooperation has been the development of a Zr-89-labeled PSMA ligand where reliable results have been obtained across various domains, including chemistry, radiochemistry, biochemistry, and preclinical research. This comprehensive process extended to feasibility studies conducted with carefully selected patients from a single nuclear medicine clinic. The approach demonstrates how far close collaboration between different disciplines within nuclear medicine can further the move towards patient-oriented radiopharmaceutical treatments while simultaneously meeting regulatory demands. With such a strategy, innovative radiopharmaceutical solutions can be brought to the market more swiftly and efficiently, in line with the needs of patients.

1 November 2005 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
KSKlaus Schomäcker
Klaus Schomäcker
MDMarkus Dietlein
Markus Dietlein
GMGynter Mödder
Gynter Mödder
BBBarbara Boddenberg-Pätzold
Barbara Boddenberg-Pätzold
BZBeate Zimmermanns
Beate Zimmermanns
HSHarald Schicha
Harald Schicha
This in-vitro study investigated the influence of the contrast agents iothalamate (Conray) and special preparations of iotrolan (Isovist) and iopromide (Ultravist) without ethylenediaminetetraacetic acid (EDTA), the anaesthetic Scandicain and the glucocorticoid triamcinolone on the stability of 90Y-, 169Er- and 186Re-radiocolloids used for radiation synovectomy. Vials of 1 ml of synovial fluid and 0.02 ml of radiocolloid suspension (0.56-3.6 MBq) were mixed with 0.06, 0.6 and 1.0 ml of each contrast agent. In an additional series, 0.1 ml of Scandicain and 0.1 ml of triamcinolone were tested. Thin layer chromatography and ultrafiltration/centrifugation were performed between 1 h and 15 days after incubation with negative and positive controls. Within 24 h, 0.6 and 1.0 ml of Conray had mobilized 5-20% of the 90Y and 169Er out of the colloids. No interference between 186Re-colloids and Conray was visible before the ninth day after incubation. Iotrolan and iopromide without EDTA had no effect on the stability at shorter incubation periods of up to 6 days. The addition of Scandicain did not produce low-molecular 90Y or 169Er in the presence of synovial fluid. The fraction of low-molecular 186Re reached 4% after 24 h. Triamcinolone did not have any effect on stability in the presence of synovial fluid. The disintegration of the radioactive colloids can be attributed to either the formation of EDTA complexes or radiolytic effects. The volume of the injected contrast agent should be as small as possible to confirm correct intra-articular distribution.

1 January 2017 in Journal of Environmental Radioactivity
Verified
Journal Article
Closed access
FSF. Sudbrock
F. Sudbrock
TFTh. Fischer
Th. Fischer
BZB. Zimmermanns
B. Zimmermanns
ADA. Drzezga
A. Drzezga
KSKlaus Schomäcker
Klaus Schomäcker